U.S. markets open in 3 hours 40 minutes
  • S&P Futures

    3,921.50
    +17.75 (+0.45%)
     
  • Dow Futures

    31,569.00
    +148.00 (+0.47%)
     
  • Nasdaq Futures

    12,090.00
    +49.50 (+0.41%)
     
  • Russell 2000 Futures

    1,782.90
    +13.10 (+0.74%)
     
  • Crude Oil

    111.19
    +1.62 (+1.48%)
     
  • Gold

    1,827.10
    +2.30 (+0.13%)
     
  • Silver

    21.31
    +0.14 (+0.65%)
     
  • EUR/USD

    1.0588
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • Vix

    27.01
    -0.22 (-0.81%)
     
  • GBP/USD

    1.2259
    -0.0011 (-0.09%)
     
  • USD/JPY

    135.9300
    +0.4840 (+0.36%)
     
  • BTC-USD

    21,066.04
    -385.72 (-1.80%)
     
  • CMC Crypto 200

    459.85
    -1.94 (-0.42%)
     
  • FTSE 100

    7,335.25
    +76.93 (+1.06%)
     
  • Nikkei 225

    27,049.47
    +178.20 (+0.66%)
     

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Vaccitech plc (NASDAQ: VACCannounced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines (VTP-300) in chronic HBV patients who are virally suppressed with oral anti-viral therapies.

  • In the VTP-300 monotherapy group, meaningful and durable reductions of HBsAg were seen in all three patients with baseline HBsAg under 50 IU/mL.

  • Related: Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial.

  • HBsAg is a hallmark of chronic hepatitis B virus (HBV) infection.

  • These three patients had 0.7, 0.7, and 1.4 log10 declines two months after the last VTP-300 and persisted in all three patients at their latest follow-up five or eight months after the last VTP-300.

  • For the first eight patients who received VTP-300 in combination with a single low dose of nivolumab at the time of the booster dose, the mean reduction in HBsAg was over 1 log10 at six months and persisted with a mean decline of 1.15 log10 at eight months after the last dose of VTP-300.

  • One patient developed a non-detectable HBsAg level, which continued eight months after the last dose of VTP-300.

  • Enrollment in the HBV002 study is complete, with 55 patients enrolled.

  • Updated interim analysis for all patients at the six-month follow-up timepoint is expected at the end of 2022.

  • Price Action: VACC shares are up 21.70% at $5.55 during the market session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.